{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:52:54Z","timestamp":1774461174964,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>This <jats:italic>Perspective<\/jats:italic> examines a recent surge of information regarding the potential benefits of acid-suppression drugs in the context of COVID-19, with a particular eye on the great variability (and, thus, confusion) that has arisen across the reported findings, at least as regards the popular antacid famotidine. The degree of inconsistency and discordance reflects contradictory conclusions from independent, clinical-based studies that took roughly similar approaches, in terms of both experimental design (retrospective, observational, cohort-based, etc.) and statistical analysis workflows (propensity-score matching and stratification into sub-cohorts, etc.). The contradictions and potential confusion have ramifications for clinicians faced with choosing therapeutically optimal courses of intervention: e.g., do any potential benefits of famotidine suggest its use in a particular COVID-19 case? (If so, what administration route, dosage regimen, duration, etc. are likely optimal?) As succinctly put this March in Freedberg et al. (2021), \u201c<jats:italic>\u2026several retrospective studies show relationships between famotidine and outcomes in COVID-19 and several do not<\/jats:italic>.\u201d Beyond the pressing issue of possible therapeutic indications, the conflicting data and conclusions related to famotidine must be resolved before its inclusion\/integration in ontological and knowledge graph (KG)\u2013based frameworks, which in turn are useful for drug discovery and repurposing. As a broader methodological issue, note that reconciling inconsistencies would bolster the validity of meta-analyses which draw upon the relevant data-sources. And, perhaps most broadly, developing a system for treating inconsistencies would stand to improve the qualities of both 1) real world evidence-based studies (retrospective), on the one hand, and 2) placebo-controlled, randomized multi-center clinical trials (prospective), on the other hand. In other words, a systematic approach to reconciling the two types of studies would inherently improve the quality and utility of each type of study individually.<\/jats:p>","DOI":"10.3389\/fphar.2021.700703","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T06:12:35Z","timestamp":1628662355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Cameron","family":"Mura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip E.","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s10620-020-06430-z","article-title":"Repurposed GI Drugs in the Treatment of COVID-19","volume":"65","author":"Aguila","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/bib\/bbr005","article-title":"Literature mining, ontologies and information visualization for drug repurposing","volume":"12","author":"Andronis","year":"2011","journal-title":"Brief. Bioinform."},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene Ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1003343","DOI":"10.1371\/journal.pcbi.1003343","article-title":"Ten quick tips for using the gene ontology","volume":"9","author":"Blake","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.12809\/hkmj208507","article-title":"Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study","volume":"160","author":"Cheung","year":"2020","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101874","DOI":"10.1016\/j.tmaid.2020.101874","article-title":"Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19","volume":"37","author":"Eldanasory","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"B7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2020.11.007","article-title":"Association between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized with COVID-19","volume":"160","author":"Elmunzer","year":"2020","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00011-020-01422-1","article-title":"Histamine receptors and COVID-19","volume":"70","author":"Ennis","year":"2021","journal-title":"Inflamm. Res."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2020.11.053","article-title":"Potential Biases in Studies of Acid Suppressing Drugs and COVID-19 Infection","volume":"160","author":"Etminan","year":"2020","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1053\/j.gastro.2020.09.028","article-title":"Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank","volume":"160","author":"Fan","year":"2021","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s11192-011-0494-7","article-title":"Negative results are disappearing from most disciplines and countries","volume":"90","author":"Fanelli","year":"2012","journal-title":"Scientometrics"},{"key":"B12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2020.12.044","article-title":"Famotidine and COVID-19","volume":"161","author":"Freedberg","year":"","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2021.01.013","article-title":"Famotidine and COVID-19: Author Reply","volume":"160","author":"Freedberg","year":"2021","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1053\/j.gastro.2020.05.053","article-title":"Famotidine Use Is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study","volume":"159","author":"Freedberg","year":"","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkaa1061","article-title":"PROMISCUOUS 2.0: a resource for drug-repositioning","volume":"49","author":"Gallo","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.mayocp.2020.05.027","article-title":"Famotidine against SARS-CoV2: A Hope or Hype?","volume":"95","author":"Ghosh","year":"2020","journal-title":"Mayo Clinic Proc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-3743-1_1","article-title":"Primer on Ontologies","volume":"1446","author":"Hastings","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101942","DOI":"10.1016\/j.pupt.2020.101942","article-title":"Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients","volume":"63","author":"Hogan Ii","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/gutjnl-2020-321852","article-title":"Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series","volume":"69","author":"Janowitz","year":"2020","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1053\/j.gastro.2021.02.028","article-title":"Lack of consistent associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19: meta-analysis of observational studies","volume":"160","author":"Kamal","year":"2021","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/17460441.2019.1586880","article-title":"A new wave of innovation in Semantic web tools for drug discovery","volume":"14","author":"Kanza","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41597-021-00799-w","article-title":"Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection","volume":"8","author":"Liu","year":"2021","journal-title":"Scientific Data"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-06875-w","article-title":"More than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?","author":"Malone","year":"2021","journal-title":"Dig. Dis. Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"633680","DOI":"10.3389\/fphar.2021.633680","article-title":"COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms","volume":"12","author":"Malone","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.14309\/ajg.0000000000000832","article-title":"Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients with COVID-19","volume":"115","author":"Mather","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2019","journal-title":"The Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1186\/s13063-020-04773-6","article-title":"The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Samimagham","year":"2020","journal-title":"Trials"},{"key":"B28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejphar.2004.12.042","article-title":"The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells","volume":"509","author":"Sasaki","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"B29","article-title":"Letter to the editor: Famotidine and mortality in COVID-19","author":"Sethia","year":"","journal-title":"Gastroenterology"},{"key":"B30","volume-title":"Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-Analysis","author":"Sethia","year":""},{"key":"B31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.14309\/ajg.0000000000001153","article-title":"Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients","volume":"116","author":"Shoaibi","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B32","article-title":"What underlies the benefit of famotidine formulations used during COVID-19?","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1126\/science.103.2684.677","article-title":"On the Theory of Scales of Measurement","volume":"103","author":"Stevens","year":"1946","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10620-021-06872-z","article-title":"Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis","author":"Sun","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"173890","DOI":"10.1016\/j.ejphar.2021.173890","article-title":"A review of potential suggested drugs for coronavirus disease (COVID-19) treatment","volume":"895","author":"Tarighi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"631139","DOI":"10.3389\/fimmu.2021.631139","article-title":"A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic","volume":"12","author":"Triggle","year":"2021","journal-title":"Front. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"W541","DOI":"10.1093\/nar\/gkr469","article-title":"BioPortal: enhanced functionality via new Web services from the National Center for Biomedical Ontology to access and use ontologies in software applications","volume":"39","author":"Whetzel","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010611-134630","article-title":"Novel computational approaches to polypharmacology as a means to define responses to individual drugs","volume":"52","author":"Xie","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2020.10.011","article-title":"Famotidine Use Is Not Associated with 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients with Coronavirus Disease 2019 from a Large Healthcare System","volume":"160","author":"Yeramaneni","year":"2021","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323668","article-title":"Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study","author":"Zhou","year":"2020","journal-title":"Gut"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.700703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T06:12:42Z","timestamp":1628662362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.700703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":40,"alternative-id":["10.3389\/fphar.2021.700703"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.700703","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"article-number":"700703"}}